|Audit||Nominating and Governance||Compensation|
|Axel Bolte, M.B.A.|
|Thomas Dyrberg, M.D., Ph.D.|
|Mike Ross, Ph.D.|
Managing Partner, SV Life Sciences
Michael Ross, Ph.D. serves as a Managing Partner of SV Life Sciences (SVLS). He was the tenth employee at Genentech, where he worked for 13 years in various roles including team leader and Vice President of Development. Dr. Ross also started Genentech's protein engineering and small molecule discovery effort as Vice President of Medicinal and Biomolecular Chemistry. He was the founding CEO of Arris Pharmaceutical, MetaXen, ExSAR and CyThera (now Novocell) and was also Managing Partner at Didyma, LLC, a biotechnology management consulting firm.
Dr. Ross currently serves or has served on the board of directors of several biotechnology companies, including Aderis Pharmaceuticals, Adimab, Alinea, Archemix, Arris Pharmaceuticals, Arsanis, Carta Proteomics, CyThera, Glycofi, Epimmune, Genencor, Ikano, Itero Biopharmaceuticals, Link Medicine, MetaXen, Mpex, NKT Therapeutics, Rempex, Rinat, Sutro Biopharmaceuticals and Xenova. He also serves on the faculty of Thayer School of Engineering at Dartmouth College.
Dr. Ross received his Bachelor of Arts (A.B.) from Dartmouth College, his Doctor of Philosophy (Ph.D.) degree in Chemistry from the California Institute of Technology (Caltech), and completed a Post-Doctorate program in Molecular Biology at Harvard University.